Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

autoimmune disease

- PMLiVE

AstraZeneca/Sanofi’s RSV antibody backed by FDA advisory committee for infants

RSV is the leading cause of hospitalisation for infants aged under one year in the US

- PMLiVE

Sanofi’s frexalimab shows promise in relapsing forms of MS

The neurological disease affects approximately 2.8 million people worldwide

- PMLiVE

Sanofi/Regeneron’s Dupixent shows promise in chronic obstructive pulmonary disease

Approximately 300,000 people in the US live with uncontrolled COPD with evidence of type 2 inflammation

Train your brain for success

In this episode of Impetus Digital‘s Fireside Chat series, Natalie Yeadon, Co-Founder and CEO of Impetus Digital sits down with Max Newlon, President of Brain Co. They discuss everything from...

Impetus Digital

- PMLiVE

Positive results for Sanofi/Regeneron’s Dupixent published in Nature Medicine

The biologic was shown to significantly improve uncontrolled prurigo nodularis symptoms

- PMLiVE

AI model shows promise in detecting lung cancer earlier

Lung cancer accounts for more than 20% of cancer deaths in the UK

ChatGPT AI copywriter: Looming threat or opportunity to evolve?

Even as someone who makes a living working in healthcare communications, I can still spend many hours copywriting without much progress – it is the nature of the beast [come...

Page & Page and Partners

- PMLiVE

Sanofi signs agreement worth up to $750m for Maze’s Pompe disease drug

The candidate has recently cleared its first phase 1 clinical trial

- PMLiVE

Moderna and IBM to explore quantum computing and AI for future mRNA medicines

A growing number of biopharmas have been investing in quantum computing over recent years

- PMLiVE

New report reveals ‘major’ financial burdens faced by atopic dermatitis patients

The report, commissioned by Sanofi, analyses the economic impact of the condition

- PMLiVE

Positive results for Sanofi’s haemophilia therapy published in The Lancet

Fitusiran reduced annualised bleeding rates by 90% compared to control arms

Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery

Dr. Shahar Keinan, Co-founder & CEO of POLARIS Quantum Biotech, explores quantum computing and AI for drug discovery, the Quantum Molecular Design process, and how POLARISqb is working to improve...

Impetus Digital

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links